Company reports financial results for the fourth quarter and full-year 2024, and will host a conference call tomorrow, March 19 at 8:30 am ET The three assets in the portfolio are in-licensed from ...

Lonza is responsible for manufacturing proprietary tech components and Sidewinder for ADC, R&D, manufacturing, and commercialization.

Detailed price information for Adc Therapeutics Sa (ADCT-N) from The Globe and Mail including charting and trades.

LYON, France, April 27, 2021 /PRNewswire/ -- Mablink Bioscience, a company developing the next generation of antibody-drug conjugates (ADC) through its proprietary hydrophilic drug-linker PSARlink™ ...

- Backed by ABL Bio, a world leader in antibody engineering, NEOK is advancing a pipeline of differentiated bispecific antibody drug conjugates for a wide range of solid tumors - Company plans to ...

While the race is on to develop antibody-drug conjugate (ADC) cancer treatments, so too is the competition to manufacture them. Hoping to gain an edge in the rapidly growing market are MilliporeSigma ...

ADC Therapeutics SA (ADCT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...

The MarketWatch News Department was not involved in the creation of this content. SHANGHAI and SUZHOU, China, Nov. 24, 2025 /PRNewswire/ -- Phrontline Biopharma ("Phrontline"), a next-generation ...

According to InvestingPro data, ADC Therapeutics currently holds a market capitalization of $378.46 million. The company's price-to-earnings (P/E) ratio stands at -1.62, reflecting its earnings ...

New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected to fund operations into 2028 ...